This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.
(R)-ketamine: A new rapid-acting antidepressant.- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms.- Predictable biomarkers for rapid-acting antidepressant response to ketamine.- Nitrous Oxide: an old compound with emerging psychotropic properties.- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants.- AMPA receptor potentiators as potential rapid-acting antidepressants.- mGlu2/3 receptor antagonists as rapid-acting antidepressants.- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
| ISBN | 978-3-030-79789-8 |
|---|---|
| Artikelnummer | 9783030797898 |
| Medientyp | Buch |
| Auflage | 1st ed. 2021 |
| Copyrightjahr | 2021 |
| Verlag | Springer, Berlin |
| Umfang | VII, 149 Seiten |
| Abbildungen | VII, 149 p. 14 illus., 9 illus. in color. |
| Sprache | Englisch |
